File photograph. / SUR

Medicines Agency authorises the clinical trial of Spain's coronavirus vaccine

The Spanish company Hipra has plans to produce 400 million doses of its PHH-1V vaccine during 2022


Spain's Agency for Medicines and Health Products (Aemps), has given the green light to the phase II clinical trial of the PHH-1V coronavirus vaccine from the Spanish company Hipra.

Prime minister Pedro Sánchez confirmed the decision just weeks after the Cabinet approved funding of around 15 million euros for phase IIb / III of the clinical trials of the vaccine. He explained that the study will be carried out in 10 Spanish hospitals and will have the participation of 1,000 patients.

“This is extraordinary news for science and Spanish society. It is a proud moment for the country”, he pointed during the launch of the Strategic Projects for Recovery and Economic Transformation (Perte) for the 'Vanguard Healthcare' public-private collaboration project, at the Carlos III Health Institute.

Sánchez was accompanied by the Minister of Finance, María Jesús Montero, the Minister of Industry, Commerce and Tourism, Reyes Maroto, the Minister of Health, Carolina Darias, and the Minister of Science and Innovation, Diana Morant.